OVB

Ovoca Bio Plc

7.50
0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Ovoca Bio Plc LSE:OVB London Ordinary Share IE00B4XVDC01 EUR0.125 (CDI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 7.50 3,015 07:47:24
Bid Price Offer Price High Price Low Price Open Price
7.00 8.00 7.50 7.50 7.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Metal Mining Services 0.24 -5.48 -6.20 - 6.12
Last Trade Time Trade Type Trade Size Trade Price Currency
08:29:38 O 2,922 7.22 GBX

Ovoca Bio (OVB) Latest News

Ovoca Bio (OVB) Discussions and Chat

Ovoca Bio Forums and Chat

Date Time Title Posts
18/5/202314:17Ovoca Bio...market cap Ј8.8, stake in Polymetal worth Ј14.8633
27/4/202311:19Viagra for women731

Add a New Thread

Ovoca Bio (OVB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:29:407.222,922210.97O
07:08:227.90312.45O
07:04:317.05312.19O
07:03:507.90312.45O

Ovoca Bio (OVB) Top Chat Posts

Top Posts
Posted at 10/5/2023 10:34 by dave4545
Good job OVB sold most of their poly shares shame they did not have the sense to sell the lot when they were £20 a share.

And still we wait for trial results.

I'm trying to be logical here but if they were no good/bad then they would have told us by now but then again I suppose that could apply if they were positive

Posted at 09/2/2023 13:30 by dave4545
Slight life on L2 now 2 bid and buy price increasing on small buying
Posted at 11/1/2023 21:21 by dave4545
Decent buying today along with a 82500 sale at 5.5p who bought in on Monday at 6p

In the 30 years I have been trading I thought the idea was to give the share a chance to get into profit but atm it looks like most are buying and selling for a loss with almost no patience.

They sold when it was NT to buy at 6p the mm who took it sends hugs and kisses.

Posted at 13/12/2022 11:12 by dave4545
OVB are not the raising type.

It's all on the trial results, if they are positive and price soars they would have no trouble securing money in the market or from a pharma.

4.6p bid now, how low does this go.

Posted at 16/11/2022 10:50 by dave4545
Like blood out of a stone getting mm's to move up in this.

6-6.3p

4 v 1

Cannot even buy 1000 shares online, bidding almost the offer price to sell 6.23p+ and they still will not move up

manipulation is rife with this stock, if it was all sales the same volume they would have marked this down 7-10%

Posted at 01/11/2022 21:29 by dave4545
I think if the trial is positive the price will do 300-500% because the current price and valuation is very bombed out.

As always there's risks but the way people are piling into stocks that are bust right now like Made and Cine this might be a more reasonable gamble given they have already had a positive outcome on a phase 111 trial.

Posted at 21/10/2022 22:56 by dave4545
Hi Mick

It's weird though, for the last 3 years it's been pumped by usual suspects time and time again and now it's actually close to the most important results in it's history
the price is a fraction of recent prices and nobody is pumping it, well maybe me but I have been here 3 years plus so I'm entitled to do that.

Weird though, lots of nibbles this week but nobody claiming them, am I dreaming it's inside, can people in the trial buy stock on the sly, would not be the last time something has leaked or inside buying

Posted at 19/10/2022 11:34 by dave4545
Not much stock around again. Clearly until it reaches a level people will sell again there is not much stock. 2 small buys had to pay decent premiums.

Still nobody seems to be around the forums on ovb except me

Posted at 04/8/2021 18:05 by hedgehog 100
Last summer was a period of excellent OVB share price performance, starting with its final results, as investors anticipated Russian marketing approval, and the same should apply this time too.

Ultimately approval last year was temporarily knocked back, but only for minor procedural 'box-ticking' stuff.
Crucially, there were no concerns raised about the drug's effectiveness or safety, which are the two key criteria:

02/10/2020 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation
" ... Ovoca has been informed that the Minzdrav has not granted the MA to BP-101 following the identification of certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier. The Company notes that no issues were highlighted by the Minzdrav regarding the safety or efficacy of BP-101 in the acquired generalized form of HSDD, which has been established by clinical data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed in 2019, all as conducted in the Russian Federation. ..."
https://uk.advfn.com/stock-market/london/ovoca-bio-OVB/share-news/Ovoca-Bio-PLC-Update-re-Russian-Marketing-Authoris/83382246

So approval this time round looks like a formality, and it could be as early as October.

Posted at 26/6/2021 20:48 by hedgehog 100
24/06/2021 07:00 UKREG Ovoca Bio PLC Annual Report and Notice of AGM
https://uk.advfn.com/stock-market/london/ovoca-bio-OVB/share-news/Ovoca-Bio-PLC-Annual-Report-and-Notice-of-AGM/85432910

Well, OVB's finals are out, as well as a new presentation on the company's website, and it all makes for very arousing reading!

The news that OVB's drug can also help with female orgasms is great news, and it underlines how OVB could have a 'licence to print money' here ... or should I say a 'licence to make women runny'!!

Last summer was a period of excellent OVB share price performance, starting with its final results, as investors anticipated Russian marketing approval, and the same should apply this time too.

Ultimately approval last year was temporarily knocked back, but only for minor procedural 'box-ticking' stuff.
Crucially, there were no concerns raised about the drug's effectiveness or safety, which are the two key criteria:

02/10/2020 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation
" ... Ovoca has been informed that the Minzdrav has not granted the MA to BP-101 following the identification of certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier. The Company notes that no issues were highlighted by the Minzdrav regarding the safety or efficacy of BP-101 in the acquired generalized form of HSDD, which has been established by clinical data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed in 2019, all as conducted in the Russian Federation. ..."
https://uk.advfn.com/stock-market/london/ovoca-bio-OVB/share-news/Ovoca-Bio-PLC-Update-re-Russian-Marketing-Authoris/83382246

So approval this time round looks like a formality, and it could be as early as October.

That should give an immediate big boost to the s.p., and should be followed by news on this:
"Discussions are progressing with a leading local candidate that can both manufacture and distribute BP-101."

Sales should then commence in Russia, the world's largest country, providing great cashflow to complement OVB's already excellent balance sheet.

And we also have the results of the Australia and New Zealand trials to look forward to, probably by the end of the year, a major step on the road to opening up other markets, including Europe and the US.

It's quite incredible that you can buy such a well-funded and proven biotech, with such massive potential, for a sub £10M. market cap.

A market cap. of £100s of millions looks very possible longer-term if the company delivers upon its potential.

Ovoca Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
OVB
Ovoca Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230530 07:53:13